A Novel Chemotherapy Regimen (SLOG) in Metastatic Pancreatic Cancer with Promising Efficacies
─NHRI has established a novel chemotherapy regimen, SLOG, with promising activity and safety profiles in the treatment of metastatic pancreatic cancer ─

November 30, 2020 Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignant disease. Nearly 80–85% of patients presented with locally advanced or metastatic diseases at the time of diagnosis, and the overall 5-year survival rate is about 8% globally. Systemic chemotherapy is the standard of care for patients with unresectable…